Critical Path Institute Announces Dr. Timothy R. Franson as Chair of C-Path’s Board of Directors

July 13, 2016

 

Critical Path Institute Announces Dr. Timothy R. Franson as Chair of C-Path’s Board of Directors

TUCSON, Ariz., July 13, 2016 — The Critical Path Institute (C-Path) is pleased to announce the appointment of Dr. Timothy R. Franson as Chair of C-Path’s Board of Directors. Franson replaces Peter B. Corr, MD, PhD, who will continue to serve as Senior Advisor to the Board.

Franson brings extensive clinical and regulatory expertise in all pre- and post-approval phases of pharmaceutical development. He currently is the Chief Medical Officer at YourEncore, a leading provider of experts-on-demand for the pharmaceutical, medical devices, and consumer goods industries. Prior to joining YourEncore, Franson was a principal at FaegreBD Consulting and Vice President of Global Regulatory Affairs & Patient Safety for Eli Lilly and Company. He is the Immediate Past President of the US Pharmacopeial Convention. Franson has represented industry in policy matters including Congressional testimony for renewals of the Prescription Drug User Fee Act, as well as serving on the National Institutes of Health/National Center for Advancing Translational Sciences (NIH/NCATS) Treatment of Rare Diseases review panel.

“This is a very exciting time at the Critical Path Institute,” said Franson. “I look forward to building on Dr. Corr’s outstanding work guiding one of the most progressive nonprofit organizations leading collaborations in regulatory science. I’m honored the Board has entrusted me with this responsibility.”

Dr. Franson earned his bachelor’s degree in Pharmacy from Drake University and his medical degree from the University of Illinois College of Medicine. He also received Internal Medicine training from the University of Iowa and completed a Fellowship in Infectious Diseases and Epidemiology at the Medical College of Wisconsin. Franson has authored more than 50 articles in the fields of infectious disease, epidemiology, pharmacoeconomics, and antibiotic utilization, as well as four book chapters relating to innovation policy topics.

“With the creation of our Data Collaboration Center to encourage the sharing of clinical trial data, as well as other collaborations with regulatory agencies, industry, and academia, C-Path is helping to articulate and advance a framework so that innovative methods rooted in evidence can advance the state of medical product development,” said Martha A. Brumfield, PhD, president and CEO of C-Path. “Tim is ideally suited to help the organization advance these efforts.”

For biographies of the C-Path Board of Directors, click here.

About the organizations:

C-Path (Critical Path Institute) is an independent, nonprofit organization established in 2005 with public and private philanthropic support from the Arizona community, Science Foundation Arizona, and the US Food and Drug Administration (FDA). C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established 12 global, public-private partnerships that currently include over 1,450 scientists from government and regulatory agencies, academia, patient advocacy organizations, and dozens of major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona. For more information, visit www.c-path.org.